GU Cancers 2019 | “All bladder, all the time” – Highlights from the 2019 Genitourinary Cancers Symposium
Arlene Siefker-Radtke, MD of the University of Texas MD Anderson Cancer Center, Houston, TX, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. She gives us a rundown of her top picks from the conference and comments on the future directions for the treatment of bladder cancer.
Transcript (edited for clarity)
At this meeting, we are certainly seeing the development of multiple novel targeted strategies. There was data presented on Sacituzumab, which is an antibody-drug conjugate. And the goal of antibody-drug conjugates are to bring a payload of a toxic agent directly to the tumor, thereby minimizing the toxicity that patients experience...
At this meeting, we are certainly seeing the development of multiple novel targeted strategies. There was data presented on Sacituzumab, which is an antibody-drug conjugate. And the goal of antibody-drug conjugates are to bring a payload of a toxic agent directly to the tumor, thereby minimizing the toxicity that patients experience.
With Sacituzumab, we’re seeing response rates in the range of 27% and a toxicity profile that when compared to historical data with MVAC and Gemcitabine Cisplatin certainly appears promising. So I’m looking forward to hearing more about Sacituzumab in the future.
Read more...
